AIM
VYNT

Acrospire Investment Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Acrospire Investment Management’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-74
Closed -$45K – 2631
2017
Q1 		$45K Buy
74
+30
+68% +$10.7K 0.04% 1046
2016
Q4 		$9K Buy
+44
New +$10K ﹤0.01% 1977
2016
Q3 		– Sell
-23
Closed -$7K – 2215
2016
Q2 		$7K Buy
+23
New +$8.09K 0.01% 1821

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return

Acrospire Investment Management's VYNT Position: Q2 2017 in Review

Acrospire Investment Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2017, closing a stake of 74 shares — an estimated $45K sold.

Acrospire Investment Management first reported a position in VYNT in Q2 2016 and held it in 3 quarters. The position peaked at $45K in Q1 2017. 28 funds tracked by Wall St. Rank hold VYNT as of Q2 2017.

  • Acrospire Investment Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 74 Vyant Bio, Inc. Common Stock shares in Q2 2017, an estimated $45K.
  • Acrospire Investment Management first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Vyant Bio, Inc. Common Stock position peaked at $45K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.